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Pharmacokinetics of flunixin meglumine in
mature swine after intravenous, intramuscular
and oral administration
Monique D Pairis-Garcia1, Locke A Karriker2*, Anna K Johnson1, Butch Kukanich3, Larry Wulf4, Suzanne Sander4,
Suzanne T Millman5, Kenneth J Stalder1 and Johann F Coetzee4
Abstract
Background: The purpose of this study was to determine intravenous (IV), intramuscular (IM) and oral (PO) FM PK
in mature swine. Appropriate pain management for lameness in swine is a critical control point for veterinarians
and producers, but science-based guidance on optimal housing, management and treatment of lameness is
deficient. Six mature swine (121–168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target
dose of 2.2 mg/kg in a cross-over design with a 10 day washout period between treatments. Plasma samples
collected up to 48 hours post-administration were analyzed by high pressure liquid chromatography and mass
spectrometry (HPLC-MS) followed by non-compartmental pharmacokinetic analysis.
Results: No adverse effects were observed with flunixin meglumine administration for all routes. Flunixin
meglumine was administered at an actual mean dose of 2.21 mg/kg (range: 2.05-2.48 mg/kg) IV, IM and PO. A
mean peak plasma concentration (CMAX) for IM and PO administration was 3748 ng/ml (range: 2749–6004 ng/ml)
and 946 ng/ml (range: 554–1593 ng/ml), respectively. TMAX was recorded at 1.00 hour (range: 0.50-2.00 hours) and
0.61 hours (range: 0.17-2.00 hours) after PO and IM administration. Half-life (T ½ λz) for IV, IM and PO administration
was 6.29 hours (range: 4.84-8.34 hours), 7.49 hours (range: 5.55-12.98 hours) and 7.08 hours (range: 5.29-9.15 hours)
respectively. In comparison, bioavailability (F) for PO administration was 22% (range: 11-44%) compared to IM F at
76% (range: 54-92%).
Conclusions: The results of the present study suggest that FM oral administration is not the most effective
administration route for mature swine when compared to IV and IM. Lower F and Cmax of PO-FM in comparison to
IM-FM suggest that PO-FM is less likely to be an effective therapeutic administration route.
Keywords: Swine, Gilt, Lameness, Flunixin meglumine, Pharmacokinetics, NSAIDs, Oral bioavailability
Background
Researchers have reported that lameness is a major fac-
tor when culling females from the swine breeding herd
[1-3]. Lameness in breeding aged swine has a large nega-
tive economic impact to livestock producers [4] and has
been highlighted as a welfare concern [5]. Lameness was
ranked as the third most common reason for culling
sows, comprising 15% of the cull market in the U.S. [6].
In addition leg soundness was identified as the most
common involuntary reason for culling sows [7]. Lame-
ness can be caused by neurological deficits, lesions of
the hoof and/or limb, mechanical-structural conforma-
tion, trauma, or metabolic and infectious disease [8,9].
Appropriate management of pain, regardless of etiology
is a critical control point for veterinarians and producers
[10]. However, science-based guidance for the industry
on optimal housing, management and treatment of lame
swine is deficient. There are currently no approved anal-
gesia drug treatments for lame swine in the U.S. [11].
Research to address the limited knowledge in this area is
essential to formulating science-based recommendations
for swine producers. In addition, providing appropriate
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drug regimens will allow caretakers and veterinarians to
manage pain effectively on farm [10,12].
Flunixin meglumine acts by decreasing prostaglandin
synthesis by inhibiting the enzyme cyclo-oxygenase
(COX; a major player in the inflammatory process). Flu-
nixin meglumine has been shown to be effective in
managing pain associated with a variety of companion
animal diseases [13,14]. Pharmaceutical advantages for
FM include its potency as a COX inhibitor and effective
analgesic strength for acute pain [15].
Flunixin-meglumine (FM) is approved in the US as an
intramuscular (IM) injection in swine, and is available
for intravenous (IV) and oral (PO) administration in
other species [11]. Flunixin meglumine has been used
exclusively within the veterinary community and is la-
beled for use in the U.S. for beef cattle, dairy cattle,
horses and swine [16]. Flunixin Meglumine is labeled for
pyrexia control associated with swine respiratory disease
at 2.2 mg/kg dose administered IM [17]. However, this
drug’s analgesic effects at the recommended dose have
not been quantified. The half maximal effective concen-
tration (EC50) of a drug is often used to measure a drug’s
potency. Although there are currently no studies that
have been conducted on EC50 of FM in swine, a study
identifying FM EC50 between 0.2-0.9 ug/ml in an arth-
ritis model in horses [18] may provide a guideline to
determine FM concentrations required to provide anal-
gesia in swine.
Although FM is not specifically labeled for pain man-
agement in swine, it can be used to alleviate pain in pigs
under the U.S. Animal Medicinal Drug Use Clarification
Act (AMDUCA).
Pharmacokinetic (PK) parameters for FM have been
evaluated in several species including cattle [19], small
ruminants [20,21], horses [18], chickens [22], and com-
panion animals [23]. To the authors’ knowledge there
have been two peer-reviewed articles published on FM
PK in swine [16,24]. However, both studies evaluated
FM-PK properties in prepubertal swine weighing bet-
ween 18.6 and 40 kg, and neither study evaluated oral
bioavailability (F) of FM. The purpose of this study was
to determine IV, IM and oral FM PK in mature swine.
Results
No adverse effects on the sow were observed following
IV, IM or PO-FM administration and drug levels were
below the limit of detection on baseline days suggesting
that the 10-day washout period provided adequate
time between rounds to prevent residual drug effects.
Weight and round had no effect (P > 0.05) but time-
point, route and time-point*route interaction were dif-
ferent (P < 0.002).
Purity analysis conducted in the lab on the oral powder
resulted in a flunixin concentration of 34 mg Flunixin/g
sample ± 10 mg Flunixin/g sample (or 3.4% ± 1% of the
powder). We analyzed the data using flunixin and not
flunixin meglumine, thus our results may be within 3-5%
higher or lower than stated results. Utilizing the concen-
tration presented on the label, sows received an actual
mean dose of 2.21 mg/kg (range: 2.05-2.48 mg/kg). Utili-
zing the results from our purity analysis sows received an
actual mean dose of 3.02 mg/kg (range: 2.04-4.36 mg/kg).
Bioavailability and mean peak plasma concentration
(Cmax) was greater for IM-FM compared to PO-FM
(P < 0.002), but time to Cmax (Tmax) was not different
(P > 0.05) between routes. Mean residence time extrapo-
lated to infinity (MRT 0-INF) was greater in IV-FM
compared to PO and IM but PO-FM and IM-FM were
not different (P > 0.05). Clearance per fraction of the
dose absorbed (Cl-F) was greater in PO-FM compared
to IV and IM-FM (P = 0.0004). Route had no effect on
elimination half-life (T ½ λz; P > 0.05).
Table 1 presents the mean plasma concentrations by
time for IV, IM and PO-FM administered at 2.2 mg/kg.
Table 2 summarizes the calculated PK for IV-FM,
IM-FM and PO-FM. The geometric mean T ½ λz
was 6.29 hours (range 4.84 to 8.34 hours) for IV-FM
resulting from a geometric mean Vz of 0.914 L/kg,
(range 0.614 – 1.38 L/kg) and a geometric mean Cl of
1.68 ml/min/kg, (range 1.40 – 2.54 ml/minute/kg). . The
geometric mean Cmax, Tmax, and T ½ λz for PO-FM
were 946 ng/mL (range 554–1593 ng/mL), 1.00 hour
Table 1 Mean (± SD, n = 6) flunixin meglumine plasma
concentrations (ng ml-1) after a single intravenous (IV),
intramuscular (IM) or oral (PO) administration in gilts
Administration route
Time (hours) IV ±SD IM ±SD PO ±SD
0.05 21695.1 4036.6 - - - -
0.10 18615.7 3638.1 - - - -
0.17 22819.35 17414.12 2830.6 1237.3 - -
0.25 - - - - 537.4 231.4
0.33 10018.9 1896.4 3100.0 1224.0 - -
0.5 8989.7 3304.1 - - 987.8 432.9
0.67 - - 3258.6 1565.2 - -
1.0 3358.1 829.9 2761.1 850.1 786.2 385.1
2.0 2005.4 663.1 2264.1 380.4 869.7 337.2
4.0 908.9 254.5 1194.8 574.3 440.2 204.1
8.0 407.1 87.6 593.2 327.0 173.7 114.7
12.0 - - - - 76.2 61.4
16.0 93.8 57.4 176.1 87.2 46.7 38.8
24.0 32.8 20.4 66.2 30.2 16.7 16.5
36.0 10.8 7.28 28.4 17.2 6.15 4.08
48.0 2.68 1.80 10.2 8.8 2.2 1.1
Time (hours) began once drug was administered.
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(range 0.50 – 2.00 hours), and 7.1 hours (range 5.29–
9.15 hours) respectively. Mean F and mean absorption
time (MAT) were determined to be 22% (range 11–
44%) and 2.57 hours (range 2.18–2.67 hours). The geo-
metric mean Cmax, Tmax, and T ½ λz for IM-FM were
3748 ng/mL (range 2749–6004 ng/mL), 0.61 hours
(range 0.17-2.00 hours), and 7.49 hours (range 5.55–
12.98 hours). Mean F and MAT were determined to
be 76% (range 54-92%) and 3.4 hours (range 2.23–
6.03 hours).
Discussion
In this study, we evaluated the PK parameters of IV,
IM and PO-FM in 42-week old mature swine (152–
168 ±11.3 kg) including F. The administrative dosages
for all routes were selected as the labeled IM dose
for swine at 2.2 mg/kg. Although FM PK properties
were previously evaluated at 2.2 mg/kg in swine [24],
the authors completed this work using younger, im-
mature pigs (8-weeks of age) and did not evaluate
PO-FM administration. Hence, the current study is
novel for evaluating mature pigs and a different ad-
ministration route using 2.2 mg/kg dose.
Intravenous FM administration is imperative in PK
studies as a means to determine F for non-IV routes.
Elimination half-life was not different between adminis-
tration routes and T ½ λz results were similar compared
to both PK studies evaluating IV-FM in swine [16,24].
The MRT at 3.01 hours and Cl at 1.68 ml/min/kg were
lower than results reported by Buur and colleagues [16]
and Yu and colleagues [24]. Although the cause of these
differences is unknown, variation between older and
younger swine may be attributed to difference in genetic
lines, body condition, or immune function. Further re-
search addressing how these factors impact drug distri-
bution and elimination should be conducted.
However, intravenous administration is difficult to per-
form on swine due to inaccessible superficial veins and
thick subcutaneous fat layers [25]. For all ages and
weights, the two most common methods for IV admi-
nistration on farm include 1. Temporary aural vein
catheterization [26] or 2. IV jugular vein injection using
a “blind stick” approach, during which blood is collected
without visualization of the vein [27,28]. Aural vein
catheterization requires a veterinarian and is an unrealis-
tic option for daily on-farm treatment. Blind-stick injec-
tion can be performed by farm personnel, but is
unreliable as it is difficult to ensure that drug is not ad-
ministered extravascularly. Thus, IV administration of
FM is impractical for on-farm use.
Possible explanations for such variation in Cmax and
lower oral F include differences in drug formulations,
delivery methods and species variation [22]. Compoun-
ded drugs in veterinary medicine do not undergo the
same regulatory quality control to assure drug purity,
potency and stability as compared to FDA approved
drugs [11]. Due to the nature of compounded drugs, a
purity analysis was performed. The company distributing
the flunixin powder stated 25 mg of flunixin meglumine/
gram of powder. The results of our purity analysis con-
cluded 35 mg ± 10 mg of flunixin/ gram of powder. Dif-
ferences between results may be attributed to use of the
flunixin compound as a standard compared to fluni-
xin meglumine or variation with equipment. However,
in vivo dissolution of the drug from the formulation pro-
vided by the company may also vary resulting in a low
oral F.
The form of the drug may have also greatly influenced
oral F. Flunixin meglumine was administered orally as a
fine powder mixed with cookie dough. It was difficult to
determine if powder may have been lost or not con-
sumed during administration as the powder was ex-
tremely fine and easily dispersed. This may have falsely
lowered oral F if some pigs did not consume the entire
dose of the drug. Previous studies evaluating PO-FM in
goats, laying hens, broilers, and horses all utilized oral
gavage as the administration method for FM [20,22,29,30].
This method, although effective, is difficult to perform on
swine and does not represent a practical option for drug
administration on farm. Pellegrinin-Masini and colleagues
[31] demonstrated decreases in F when FM was mixed
with molasses and administered on the back of the tongue
Table 2 Geometric mean (± SD, n = 6) flunixin meglumine
pharmacokinetic parameters after a single intravenous
(IV), intramuscular (IM) or oral (PO) administration in
gilts (2.2 mg/kg -1)
Parameter Units Administration Route
IV ±SD IM ±SD PO ±SD
AUC EXTRAP % 0.1 0.08 0.5 1.2 0.6 0.29
AUC INF h*ng/ml 21635 3966.7 16849 4257.7 4836 2333.0
C0d ng/ml 24960 5378.2 - - - -
Cle h 1.68 0.38 - - - -
T ½ λz h 6.29 1.03 7.49 2.54 7.08 1.33
λz 1/h 0.11 0.01 0.09 0.03 0.10 0.02
MRT 0-INF h 3.01 0.63 6.41 1.85 5.58 0.86
Vss l/kg 0.30 0.07 - - - -
Vz l/kg 0.91 0.26 - - - -
CMax ng/ml 3748 1110.8 946 401.2
TMax h 0.61 0.59 1.00 0.75
F - - 0.76 0.02 0.22 0.11
Flunixin meglumine noncompartmental pharmacokinetics (WinNonlin 5.2,
Pharsight Inc. Cary NC, USA). AUC extrapolated percent of the AUC
extrapolated, AUCINF area under the curve extrapolated to infinity,
CMAX maximum plasma concentration, T ½ λz terminal half-life, λz terminal
rate constant, MRT mean residence time extrapolated to infinity, TMAX time
to CMAX, F fraction of the dose absorbed.
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with a syringe (purpose of method was to mimic clinical
practice). Bioavailability with syringe administration in
comparison to oral gavage dropped approximately 14%
[30]. Other administration options that could have been
utilized include mixing the FM powder with feed. How-
ever it should be noted that under current AMDUCA pol-
icies extra-label drug use in feed is illegal [11]. Because
this is the first published report of PO-FM F in swine, we
cannot rule out that the low oral F is due to species var-
iation. Further studies utilizing different FM oral forms
and administrative techniques (oral gavage, drug-feed
mixture) in swine should be performed.
By definition, the “half maximal effective concen-
tration (EC50) refers to the concentration of a drug, an-
tibody or toxicant which induces a response halfway
between the baseline and maximum after some specified
exposure time. It is commonly used as a measure of
drug's potency” [32]. No studies have been conducted on
FM EC50 in swine but a study conducted in the horse
determined the EC50 of FM to be between 0.2-0.9 ug/ml
[21] determined FM EC50 in horses using a chemically
induced arthritis model and evaluating thromboxane A
generation (an index for NSAID therapeutic effect in
horses; [33]. Although inter-species extrapolations of
EC50 drug values may not always be accurate, data gen-
erated from this chemically induced arthritis model in
the horse may be used as an initial starting point to pre-
dict the drug concentration required to provide effective
analgesia in lame swine. In this present study, a single
dose of flunixin at 2.2 mg/kg administered either IM or
IV resulted in sustained drug concentrations > 0.2 ug/ml
for up to 8, whereas FM administered PO sustained
these effective drug concentrations for only 4 hours. It
should be noted that IM-FM administration yielded an
average drug concentration of 0.18 ug/ml at 16 hours
post administration suggesting that an Ec50 > 0.2 ug/ml
may be achieved between 8 and 16 hours.
Methods
This study was approved by the Institutional Animal
Care and Use Committee at Iowa State University.
Animals and housing
Six healthy 42-week old Newsham genetic gilts (152–
168 ±11.3 kg) were used for this study. Gilts were
confirmed to be healthy by physical examination by a
veterinarian. Gilts were obtained from a commercial pro-
duction unit in Iowa and were acclimated to personnel for
7 days prior to study commencement. When off trial
(defined as gilts not receiving the drug and having no
blood collected), gilts were housed in individual pens.
Each pen measured 3.7 m length × 1.4 m width × 1.2 m
height and had a solid concrete floor with a rubber mat
(2.4 m length × 2 cm height × 1.4 m width). Metal fences
(1.2 m height × 76 cm width) were affixed to the end of
each home pen. Gilts were provided ad libitum access to
water via one nipple drinker (Trojan Specialty Products
Model 65, Dodge City, KS). Gilts were hand-fed a custom
mixed diet free of antibiotics or medications com-
posed of corn, soybean meal and soy hulls, designed
to meet or exceed nutrient requirements for gilts. Ap-
proximately 1.8 kg of feed was fed at 0800 and
0.45 kg of feed was fed at 1600 onto a raised con-
crete step (55 cm length × 55 cm in width × 24 cm).
Matrix (Altrenogest formulation; Intervet/Schering-
Plough, Milsboro, DE- Dose: 6.8 ml-15 mg) was added to
one kg of feed daily to prevent estrus cycle initiation.
Twenty-four hours before study commencement, gilts
were moved to individual gestation stalls (2.1 m length ×
0.6 m width) with nonslip rubber flooring. Gilts had ac-
cess to the same type of nipple drinker previously de-
scribed for the pen, and gilts remained in their stalls for
a total of 72 hours while on trial (on trial defined as gilts
receiving drug and having blood collected). Gilts on trial
regardless of administration route were fed on the same
schedule with the following ration: Day 1: 0.22 kg at
6:30, 0.45 kg at 8:50, 1.36 kg at 9:20, and .45 kg 16:15;
Day 2: 1.8 kg at 8:15 and 0.45 kg at 16:15. All gilts
returned to their individual pens between trials. Lights
were on a 12:12 light dark cycle (light hours [0600
and 1800]).
Attitude, appetite, and blood collection sites of sows
were monitored twice daily during each study period
and each sow was assessed for adverse reactions to drug
administration. Post-mortem injection site tissue damage
was not evaluated.
Study design
A cross-over design study [34] was conducted over three
rounds such that all sows received each administrative
route. Gilts were blocked by body weight and randomly
allocated to one of three administration routes for the
first round. Using the closest available data on FM in
swine, a 10-day washout period was chosen as it was
greater than 30 times the half-life reported in swine
[16,24]. Gilts were weighed 20 h before initiating the
study and these weights were used to calculate drug dos-
ages. For oral administration, the dose was rounded to
the nearest whole gram. For intravenous and intramus-
cular administration, the dose was rounded to the nea-
rest half or whole milliliter.
In the first round, two gilts were administered an
intravenous injection of FM (IV-FM) at 2.2 mg/kg
(Banamine-S® 50 mg/ml solution for injection; Schering-
Plough Animal Health Corp., Union, NJ, USA Lot #
1155103) as a single bolus injection in the right jugular
vein using a 25.4 mm 16 gauge hypodermic needle. Two
gilts received FM per os (PO-FM) at 2.2 mg/kg (Flunixin
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meglumine 500 mg/20 gm apple flavored powder pac-
ket for oral administration; Wedgewood Compounding
Pharmacy, Swedesboro, NJ, USA Lot # 2011908@2). Pow-
der was mixed with approximately 24 g of sugar cookie
dough (sows had been previously trained using cookie
dough as a positive reinforcement), divided into three, 8
gram round balls, and administered in a clean feeding
bowl. An intramuscular injection (IM-FM) of 2.2 mg/kg
flunixin meglumine was given to the remaining two gilts
(Banamine-S® 50 mg/ml solution for injection; Schering-
Plough Animal Health Corp., Union, NJ, USA Lot #
1155103). Drug was administered as two individual injec-
tions no greater than 5 ml volume into the neck muscles
using a 77 mm 18 gauge needle. This process was re-
peated over two additional rounds so that all gilts received
all FM routes. The experimental unit was the individual
gilt (n = 6/treatment). This experimental design provided
robust control of intra- and inter-animal physiological re-
sponse variations reduced the experimental units (gilts)
required.
Blood collection
All blood samples (9.0 mL/sample) were collected via
the left or right jugular vein using a 25.4 mm 16 gauge
hypodermic needle (Air-Tite Products, Virginia Beach,
VA, USA) and 12 ml luer lock syringe (TycoHealth Care,
Mansfield, MA, USA). During blood collection, gilts
were manually restrained using a pig snare. Blood was
collected from gilts receiving IV-FM at 0.05, 0.1, 0.17,
0.33, 0.5, 1, 2, 4, 8, 16, 24, 36 and 48 hours after drug ad-
ministration. For time-point 0.05 hours and 0.1 hour,
blood was collected from the left jugular vein that was
not used to administer the drug. Blood was collected
from gilts receiving PO-FM at 0.25, 0.5, 1, 2, 4, 8, 12, 16,
24, 36, and 48 hours after PO administration. Blood was
collected from gilts receiving IM-FM at 0.17, 0.33, 0.67,
1, 2, 4, 8, 16, 24, 36, and 48 hours after IM injection. A
baseline sample was collected 20 hours prior to drug ad-
ministration for all routes. Samples were immediately
transferred to a sodium heparin 10 ml blood collection
tube (BD Vacutainer, Franklin Lakes, NJ, USA) and
stored on ice before processing. Blood samples remained
on ice for no longer than 130 minutes prior to centrifu-
gation for 10 minutes at 1,500 g. Collected plasma was
placed in cryovials and frozen at −70°C until analysis.
All samples were analyzed within 70 days after sam-
ple collection and within 3 consecutive days once ana-
lysis began.
HPLC/MS analysis of FM concentrations
Plasma FM concentrations were determined using high-
pressure liquid chromatography (Surveyor MS Pump
and Autosampler, Thermo Scientific, San Jose, CA, USA)
and mass spectrometry (TSQ Quantum Discovery MAX,
Thermo Scientific, San Jose, CA, USA). Plasma samples
(0.20 ml) and the internal standard (Flunixin-d3; 40 ug
(10 μL of 4.0 ng/ml)) were treated with 20 μL of 30%
perchloric acid. Samples were vortexed for 5 seconds and
centrifuged for 20 minutes at 2,500 × g to precipitate the
sediment. The supernatant (~80 μL) was pipetted into a
glass insert containing 120 μL of 1.9% ammonium hydrox-
ide in 25% aqueous acetonitrile and fitted to an injection
vial. The injection volume equaled 12.5 μL. Two mobile
phases utilized were as follows: A. 0.1% formic acid in
water B. 0.1% formic acid in an acetonitrile at a flow rate
of 0.250 mL/min. The mobile phase began at 15% B with
a linear gradient to 95% B at 7 minutes, which was
maintained for 1.5 minutes, followed by a re-equilibration
to 15% B. Separation was achieved with a solid-core c18
column (KinetexXB -C18, 100 mm× 2.1 mm, 2.6 μm par-
ticles, Phenomenex, Torrance, CA, USA) maintained at
40°C. Flunixin meglumine eluted at 6.94 minutes. Three
SRM transitions were monitored for FM and 3 SRM tran-
sitions were used with the internal standard, FM-d3. The
quantifying ions for FM were 109, 267, and 279 m/z. Se-
quences consisting of plasma blanks, calibration spikes,
and FM plasma samples were batch processed with a pro-
cessing method developed in the Xcalibur software
(Thermo Scientific, San Jose, CA, USA). The processing
method automatically identified and integrated each peak
in each sample and calculated the calibration curve based
on a weighted (1/X) linear fit. Plasma FM concentrations
in unknown samples were calculated by the Xcalibur soft-
ware based on the calibration curve. Results were then
viewed in the Quan Browser portion of the Xcalibur soft-
ware. The standard curve in gilt plasma was linear
from 0.005 to 10 μg/mL. The coefficient of determin-
ation (R squared) exceeded 0.998 and all measured
values were within 15% of the actual values with most
of the values less than 7% difference from the actual
values. The limit of quantification for this assay was
determined to be 0.005 ug/mL, while the limit of de-
tection was at 0.001 ug/mL.
Pharmacokinetic analysis
Pharmacokinetic analyses for plasma flunixin concentra-
tions over time were performed with computer software
(WinNonlin 5.2, Pharsight Corporation, Mountain View,
CA, USA) and analyzed using non-compartmental me-
thods [35].The parameters included the area under the
curve from time 0 to infinity (AUCINF) using the linear
trapezoidal rule, percent of the AUC extrapolated to in-
finity (AUC EXTRAP), plasma clearance (Cl), first-order
rate constant (λz), terminal half-life (T½ λz), apparent
volume of distribution at steady state (Vss), apparent
volume of distribution of the area (Vz), mean residence
time extrapolated to infinity (MRT), and mean absorp-
tion time (MAT). The maximum plasma concentration
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(CMAX) and the time to maximum plasma concentration
(TMAX) were observed for PO and IM administration.
The concentration at time 0 (C0) was calculated by log-
linear regression using the first two time points after IV
administration. The AUCEXTRAP was determined by mul-
tiplying the last measured plasma concentration by the λz.
The range of the λz was determined by visual inspection
of the plasma profile and determined by linear regression
of time and natural log (ln) of the plasma concentration.
The Vz was determined by dividing the drug dose by
λz *AUCINF. The Vss was determined by multiplying the
MRT by the Cl. The Cl was determined by dividing the
dose by AUC. The F was estimated by dividing the oral
(AUC/Dose) by the IV (AUC/Dose) for each individual
animal. The MAT was estimated by subtracting the IV
MRT from the PO MRT. A 13.9% variation within sam-
ples was detected as compared to the internal standard
response across all samples.
Purity analysis
Flunixin concentration in the powder (Wedgewood
Compounding Pharmacy) was quantified using high per-
formance liquid chromatography with mass spectrometry
detection (Finnigan LTQ, Thermo Scientific, San Jose, CA,
USA). The flunixin meglumine standard (Sigma Aldrich)
and flunixin powder were dissolved in methanol and
vortexed, heated, and sonicated to ensure complete dis-
solution of flunixin and then further diluted with 25%
acetonitrile. Mobile phase consisted of a gradient of
water and acetonitrile with a flow rate ramp starting at
0.265 mL/min and increasing to 0.3 ml/min. A C18 co-
lumn (ACE 3 C18, 150 × 2.1 mm, 3 μm) was used for se-
paration with elution occurring at 12.53 minutes. Mass
spectrometry detection was achieved using electrospray
ionization in positive ion mode as previously described.
Statistical analysis
Data were analyzed using SAS software version 9.3 (SAS
Institute Inc. Cary, NC, USA).
Drug concentrations were analyzed using PROC
GLIMMIX procedures of SAS. The statistical model in-
cluded the fixed effect of route (IV vs. IM v. PO), time
point, round (1 vs. 2 vs. 3), timepoint*route interaction,
and weight as a linear covariate. Sow was included as a
random effect, and a repeated statement with sow as
the subject was also used. Fixed effect least square
means were separated using the PDIFF option in SAS.
A P-value of ≤ 0.05 was considered to be significant
for the GLIMMIX analysis of variance and when sepa-
rating means.
Conclusions
The results of the present study suggest that depending
on specific formulation used, FM oral administration in
swine may not provide the most effective administration
route for mature swine when compared to IV and IM
administration routes. Lower F and Cmax of PO-FM in
comparison to IM-FM suggest that PO-FM clinical ef-
ficacy is predicted to be a less effective therapeutic ad-
ministration route. If the EC50 for FM is similar in swine
as was presented in the arthritis model in horses, FM
may provide analgesic effects up to 8 hours after drug
administration.
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